Insmed to Participate in August Investor Conferences
07 Août 2013 - 3:00PM
Marketwired
Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company
focused on developing and commercializing an inhaled anti-infective
to treat patients battling serious lung diseases that are often
life-threatening, today announced that members of the Company's
management team will deliver corporate presentations at the
following investor conferences.
- Matthew Pauls, Chief Commercial Officer of Insmed, will present
a corporate overview at the Wedbush Pac Grow Life Sciences' 2013
Life Sciences Management Access Conference taking place from August
13-14, at Le Parker Meridian in New York City. Mr. Pauls'
presentation will take place on August 13th at 2:30 p.m. Eastern
time.
- Will Lewis, President and Chief Executive Officer of Insmed,
will address investors at Canaccord Genuity's 33rd Annual Growth
Conference taking place from August 14-15, at the Intercontinental
Hotel in Boston. Mr. Lewis' presentation will be delivered on
August 14th at 5:00 p.m. Eastern time.
Mr. Pauls' and Mr. Lewis' presentations will be webcast live on
the internet and can be accessed by visiting the investors section
of the company's website at www.insmed.com. A replay of the
webcasts will be archived on the Insmed website for 90 days
following the presentation.
About Insmed
Insmed Incorporated is a biopharmaceutical company dedicated to
improving the lives of patients battling serious lung diseases.
Insmed is focused on the development and commercialization of
ARIKACE®, or liposomal amikacin for inhalation, for at least two
identified orphan patient populations: cystic fibrosis (CF)
patients with Pseudomonas aeruginosa lung infections and patients
with non-tuberculous mycobacteria (NTM) lung infections. For more
information, visit www.insmed.com.
Forward-looking statements:
This release contains forward-looking statements. Words, and
variations of words, such as "intend," "expect," "will,"
"anticipate," "believe," "continue," "propose" and similar
expressions are intended to identify forward-looking statements.
Investors are cautioned that such statements in this release,
including statements relating to the status, results and timing of
clinical trials and clinical data, the anticipated benefits of
Insmed's products, the anticipated timing of regulatory
submissions, and the ability to obtain required regulatory
approvals, bring products to market and successfully commercialize
products constitute forward-looking statements that involve risks
and uncertainties that could cause actual results to differ
materially from those in the forward-looking statements. Such risks
and uncertainties include, without limitation, failure or delay of
European, Canadian, U.S. Food and Drug Administration and other
regulatory reviews and approvals, competitive developments
affecting the Company's product candidates, delays in product
development or clinical trials or other studies, patent disputes
and other intellectual property developments relating to the
Company's product candidates, unexpected regulatory actions, delays
or requests, the failure of clinical trials or other studies or
results of clinical trials or other studies that do not meet
expectations, the fact that subsequent analyses of clinical trial
or study data may lead to different (including less favorable)
interpretations of trial or study results or may identify important
implications of a trial or study that are not reflected in
Company's prior disclosures, and the fact that trial or study
results or subsequent analyses may be subject to differing
interpretations by regulatory agencies, the inability to
successfully develop the Company's product candidates or receive
necessary regulatory approvals, inability to make product
candidates commercially successful, changes in anticipated
expenses, changes in the Company's financing requirements or
ability raise additional capital, and other risks and challenges
detailed in the Company's filings with the U.S. Securities and
Exchange Commission, including its Annual Report on Form 10-K for
the year ended December 31, 2012. Investors are cautioned not to
place undue reliance on any forward-looking statements that speak
only as of the date of this news release. The Company undertakes no
obligation to update these forward-looking statements to reflect
events or circumstances or changes in its expectations.
Contacts: LHA Anne Marie Fields Senior Vice President
212-838-3777 afields@lhai.com Bruce Voss Managing Director
310-691-7100 bvoss@lhai.com
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024